ALDH2 activator 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


«12
  • ||||||||||  Journal, IO Biomarker:  Aldehyde dehydrogenase 2 protects cardiomyocytes against lipotoxicity via the AKT/glycogen synthase kinase 3 beta pathways. (Pubmed Central) -  Nov 12, 2020   
    The results suggested that aldehyde dehydrogenase 2 is cardioprotective against lipotoxic cardiomyopathy, probably by reducing apoptosis through the AKT/glycogen synthase kinase 3 beta (GSK-3β) pathway. Our findings partially revealed the molecular mechanism of aldehyde dehydrogenase 2's cardioprotective effect against lipotoxic injury, and suggest a new therapeutic strategy to treat lipotoxic cardiomyopathy.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] ROLE OF MITOCHONDRIA IN CHLOROACETALDEHYDE HEPATOTOXICITY () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_1207;    
    Activating ALDH2 by Alda-1 or reducing mitochondrial ROS by MitoQ can attenuate cytotoxicity of CAA in rat hepatocytes. Taken together, these findings are consistent with the conclusion that ALDH2 is involved in CAA metabolism and that mitochondrial oxidative stress may play an important role in CAA toxicity in hepatocytes.